UBS Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-9,848
| Closed | -$3K | – | 11845 |
|
|
2022
Q3 | $3K | Sell |
9,848
-11,428
| -54% | -$4.52K | ﹤0.01% | 9674 |
|
|
2022
Q2 | $8K | Buy |
+21,276
| New | +$10.8K | ﹤0.01% | 8421 |
|
|
2022
Q1 | – | Sell |
-7,561
| Closed | -$17K | – | 11405 |
|
|
2021
Q4 | $17K | Sell |
7,561
-54,932
| -88% | -$186K | ﹤0.01% | 8121 |
|
|
2021
Q3 | $286K | Sell |
62,493
-2,601
| -4% | -$11.4K | ﹤0.01% | 5075 |
|
|
2021
Q2 | $289K | Buy |
65,094
+61,253
| +1,595% | +$312K | ﹤0.01% | 5105 |
|
|
2021
Q1 | $28K | Buy |
3,841
+766
| +25% | +$6.3K | ﹤0.01% | 7079 |
|
|
2020
Q4 | $23K | Buy |
3,075
+2,934
| +2,081% | +$19.6K | ﹤0.01% | 6854 |
|
|
2020
Q3 | $1K | Sell |
141
-3,737
| -96% | -$28.4K | ﹤0.01% | 7880 |
|
|
2020
Q2 | $33K | Sell |
3,878
-969
| -20% | -$6.38K | ﹤0.01% | 6211 |
|
|
2020
Q1 | $24K | Sell |
4,847
-5,486
| -53% | -$42.7K | ﹤0.01% | 6384 |
|
|
2019
Q4 | $74K | Buy |
10,333
+3,993
| +63% | +$36.1K | ﹤0.01% | 6155 |
|
|
2019
Q3 | $69K | Buy |
6,340
+4,839
| +322% | +$51.8K | ﹤0.01% | 5998 |
|
|
2019
Q2 | $20K | Buy |
1,501
+1,454
| +3,094% | +$19.3K | ﹤0.01% | 6626 |
|
|
2019
Q1 | $0 | Sell |
47
-2,956
| -98% | -$27.5K | ﹤0.01% | 8347 |
|
|
2018
Q4 | $31K | Buy |
+3,003
| New | +$36.3K | ﹤0.01% | 6477 |
|
UBS Group's LOGC Position: Q4 2022 in Review
UBS Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 9,848 shares — an estimated $3K sold.
UBS Group first reported a position in LOGC in Q4 2018 and held it in 15 quarters. The position peaked at $289K in Q2 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- UBS Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- UBS Group sold 9,848 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $3K.
- UBS Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 15 quarters.
- UBS Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $289K in Q2 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.